Eptifibatide Uses, Dosage, and Side Effects Explained

Summary of Key Points

Eptifibatide is a medication used to prevent blood clots in individuals with certain heart conditions, such as acute coronary syndrome, unstable angina, and during procedures like percutaneous coronary intervention (PCI). It works by stopping platelets from clumping together and forming clots. Eptifibatide is typically administered through an IV in a hospital setting. Always consult your doctor before starting or adjusting any medication.

Names of Medication

US Brand Name: Integrilin (Eptifibatide)

The generic name refers to the active ingredient, while the brand name is assigned by the manufacturer. In this case, Eptifibatide is the generic name, and Integrilin is the brand name.

Pharmacologic Category

Eptifibatide belongs to the class of Glycoprotein IIb/IIIa Inhibitors, which are used to prevent platelet aggregation and blood clot formation.

Eptifibatide Dosing Guidelines

Eptifibatide is used to treat various heart-related conditions. The dosing may vary depending on the specific condition being treated. Always follow your doctor’s instructions and consult them before making any changes to your dose. If you need to speak with a healthcare provider, you can schedule a telemedicine appointment with one of our doctors.

1. Acute Coronary Syndrome (ACS): Initial dose of 180 mcg/kg IV bolus, followed by a continuous infusion of 2 mcg/kg/min for up to 72 hours.
2. Unstable Angina: Initial dose of 180 mcg/kg IV bolus, followed by a continuous infusion of 2 mcg/kg/min for up to 72 hours.
3. Myocardial Infarction (Heart Attack): Initial dose of 180 mcg/kg IV bolus, followed by a continuous infusion of 2 mcg/kg/min for up to 72 hours.
4. Percutaneous Coronary Intervention (PCI): Initial dose of 180 mcg/kg IV bolus, followed by a second bolus 10 minutes later, and a continuous infusion of 2 mcg/kg/min for 18-24 hours post-procedure.
5. Coronary Artery Disease (CAD): Dosing is similar to that for PCI, with adjustments based on the patient’s condition.
6. Thrombosis: Initial dose of 180 mcg/kg IV bolus, followed by a continuous infusion of 2 mcg/kg/min for up to 72 hours.
7. Ischemic Heart Disease: Dosing is similar to that for ACS and PCI, with adjustments based on the patient’s needs.
8. Atherosclerosis: Dosing is typically aligned with treatment for ACS or PCI.
9. Angina Pectoris: Initial dose of 180 mcg/kg IV bolus, followed by a continuous infusion of 2 mcg/kg/min for up to 72 hours.

Dosage Forms and Strengths

Eptifibatide is available in the following dosage forms:

1. Solution for injection: 0.75 mg/mL
2. Solution for injection: 2 mg/mL

Administration Instructions for Eptifibatide

Eptifibatide is administered through an intravenous (IV) line, typically in a hospital setting. It is crucial to follow the healthcare provider’s instructions carefully. The medication is given as an initial bolus (a single, large dose) followed by continuous infusion. If you are receiving this medication, your healthcare team will monitor you closely for any side effects or complications. If you have any concerns, you can schedule a telemedicine consultation with one of our doctors.

Eptifibatide Side Effects and Adverse Reactions

Like all medications, Eptifibatide can cause side effects. Some are more common, while others are rare but serious. If you experience any side effects, contact your healthcare provider immediately.

Common Side Effects

1. Bleeding: Eptifibatide increases the risk of bleeding, especially at the injection site or from areas like the gums or nose.
2. Low blood pressure (hypotension): Some patients may experience a drop in blood pressure, leading to dizziness or fainting.

Less Common Side Effects

1. Nausea: Some patients may feel nauseous after receiving the medication.
2. Headache: Mild headaches can occur but are usually temporary.

Serious Side Effects (Rare)

1. Severe bleeding: In rare cases, severe bleeding may occur, requiring immediate medical attention.
2. Allergic reactions: Symptoms like rash, itching, or difficulty breathing may indicate an allergic reaction and require emergency care.

Contraindications for Eptifibatide

A contraindication is a specific situation or condition where a medication should not be used because it may cause harm. If you have any of the following conditions, you should not take Eptifibatide. Always consult with your healthcare provider, and if you are unsure, you can speak with one of our providers through telemedicine.

1. Active internal bleeding: Eptifibatide prevents blood clots, so if you are already experiencing active bleeding, this medication could worsen the condition.
2. History of bleeding disorders: If you have a condition like hemophilia or other bleeding disorders, Eptifibatide may increase your risk of excessive bleeding.
3. Severe uncontrolled high blood pressure (hypertension): High blood pressure can increase the risk of bleeding in the brain, and Eptifibatide could heighten this risk.
4. Recent stroke: If you’ve had a stroke within the past 30 days, Eptifibatide could increase the risk of further bleeding in the brain.
5. Major surgery or trauma within the last 6 weeks: Eptifibatide can interfere with the body’s ability to form clots, which is crucial for healing after surgery or injury.
6. Severe kidney disease: Eptifibatide is processed by the kidneys, and if your kidneys are not functioning well, the drug could accumulate in your system, increasing the risk of side effects.
7. Allergy to Eptifibatide or similar medications: If you have a known allergy to Eptifibatide or similar medications, taking it could cause a severe allergic reaction.

Drug to Drug Interactions with Eptifibatide

Several medications can interact with Eptifibatide, potentially increasing the risk of side effects or reducing the effectiveness of either drug. It’s important to inform your healthcare provider about all the medications you are currently taking, including over-the-counter drugs and supplements. Below are some common medications that may interact with Eptifibatide:

1. Anticoagulants: Drugs like warfarin (Coumadin) or heparin can heighten the risk of bleeding when used alongside Eptifibatide.
2. Nonsteroidal anti-inflammatory drugs (NSAIDs): Medications such as ibuprofen (Advil, Motrin) or naproxen (Aleve) may also increase the likelihood of bleeding when taken with Eptifibatide.
3. Thrombolytics: Drugs like alteplase (Activase) or streptokinase (Streptase), which dissolve blood clots, can further elevate the risk of bleeding if combined with Eptifibatide.
4. Other antiplatelet drugs: Medications like clopidogrel (Plavix) or aspirin can increase the risk of bleeding when used together with Eptifibatide.

Eptifibatide in Pregnancy: Is It Safe?

The safety of Eptifibatide during pregnancy has not been fully established. It is classified as a Category B drug by the FDA, meaning that animal studies have not shown harm to the fetus, but there are no well-controlled studies in pregnant women. If you are pregnant or planning to become pregnant, it’s essential to discuss the potential risks and benefits of taking Eptifibatide with your healthcare provider. You may also consult one of our telemedicine providers for personalized advice.

Can You Take Eptifibatide While Breastfeeding?

It is unclear whether Eptifibatide passes into breast milk. Due to the potential for serious side effects in a nursing infant, it’s important to consult your healthcare provider about whether to discontinue breastfeeding or stop taking the medication. If you are breastfeeding and need to take Eptifibatide, your healthcare provider can help you explore your options.

Estimated Cost of Eptifibatide

The cost of a 30-day supply of Eptifibatide without insurance can vary. However, with a GoodRx coupon, the price typically ranges from $150 to $300. Prices may fluctuate depending on your location and the pharmacy you use. Be sure to check with your pharmacy for the most accurate pricing.

Possible Alternatives to Eptifibatide

If Eptifibatide is not the right medication for you, other treatment options are available depending on your condition. Always consult your healthcare provider before making any changes to your treatment plan. You can also schedule a telemedicine appointment with one of our providers to discuss alternatives.

1. Acute coronary syndrome: Alternatives may include other antiplatelet medications like clopidogrel (Plavix) or prasugrel (Effient), along with lifestyle changes such as quitting smoking, adopting a heart-healthy diet, and engaging in regular physical activity.
2. Unstable angina: Medications like beta-blockers, nitrates, or calcium channel blockers may be prescribed. Lifestyle changes, including stress management and dietary adjustments, can also be beneficial.
3. Myocardial infarction (heart attack): Other antiplatelet drugs like ticagrelor (Brilinta) or aspirin may be used. In some cases, procedures such as angioplasty or coronary artery bypass surgery may be necessary.
4. Percutaneous coronary intervention (PCI): Alternatives include other antiplatelet drugs like clopidogrel (Plavix) or ticagrelor (Brilinta). Your healthcare provider can help determine the best option for you.
5. Coronary artery disease (CAD): Statins, ACE inhibitors, and lifestyle changes like improving diet and increasing physical activity are common alternatives.
6. Thrombosis: Anticoagulants such as warfarin (Coumadin) or newer agents like apixaban (Eliquis) may be considered as alternatives.
7. Ischemic heart disease: Medications like nitrates, beta-blockers, or ACE inhibitors may be used, along with lifestyle changes such as smoking cessation and regular exercise.
8. Atherosclerosis: Statins, fibrates, or lifestyle changes such as adopting a low-fat diet and increasing physical activity may be recommended.
9. Angina pectoris: Nitrates, beta-blockers, or calcium channel blockers may be used as alternatives. Lifestyle changes, such as reducing stress and improving diet, can also help manage symptoms.

Recent Updates on Eptifibatide Research

Recent studies have explored the use of Eptifibatide in combination with other antiplatelet therapies to improve outcomes in patients undergoing percutaneous coronary interventions (PCI). Ongoing research is focused on determining optimal dosing strategies and evaluating the long-term safety of Eptifibatide in various populations, including those with chronic kidney disease. Additionally, there is growing interest in investigating the use of Eptifibatide in patients with a high risk of bleeding, aiming to better tailor treatment plans. As new findings emerge, it’s important to stay informed and discuss any updates with your healthcare provider. You can also schedule a telemedicine consultation with one of our providers to discuss the latest research and how it may impact your treatment plan.

James Kingsley

Learn More